RER− cancers (n=137) | RER+ cancers (n=22) | OR (95% CI) | p Value | |
K-ras mutation2-150 | ||||
Absent | 90 (69%) | 19 (86%) | 0.40 (0.08–1.37) | 0.132-151 |
Present | 40 (31%) | 3 (14%) | ||
p53 immunostaining | ||||
Absent | 77 (56%) | 10 (46%) | 1.52 (0.57–4.17) | 0.482-152 |
Present | 60 (44%) | 12 (55%) | ||
c-erbB-2 immunostaining2-150 | ||||
Absent | 85 (66%) | 9 (45%) | 2.38 (0.85–6.95) | 0.112-152 |
Present | 43 (34%) | 11 (55%) | ||
c-myc immunostaining2-150 | ||||
Absent | 53 (42%) | 6 (30%) | 1.60 (0.19–1.81) | 0.462-152 |
Present | 74 (58%) | 14 (70%) |